DPP-4 inhibitors are effective in controlling blood glucose levels, have a low risk of hypoglycemia, are well tolerated in patients with T2D and diabetic kidney disease (DKD), and are expected to reduce the progression of diabetic nephropathy. The gene discussed is DPP4; the disease is Hypoglycemia.